Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma

Annals of Clinical and Laboratory Science

Volumn 27, Issue 5, 1997, Pages 351-357

  Tozuka, Minoru ^a   Yamauchi, Kazuyoshi ^a   Hidaka, Hiroya ^a   Nakabayashi, Tetsuo ^a   Okumura, Nobuo ^b   Katsuyama, Tsutomu ^c  

^a SHINSHU UNIVERSITY HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ASPARAGINASE; FIBRINOGEN; LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE; PREDNISOLONE; PROTEIN; TRIACYLGLYCEROL; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGAR GEL ELECTROPHORESIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPERTRIGLYCERIDEMIA; ISOELECTRIC FOCUSING; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOLIPOPROTEINS; APOLIPOPROTEINS C; APOLIPOPROTEINS E; ASPARAGINASE; BLOOD PROTEIN ELECTROPHORESIS; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; ELECTROPHORESIS, AGAR GEL; FIBRINOGEN; HUMANS; HYPERTRIGLYCERIDEMIA; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIPOPROTEINS; LYMPHOMA; PREDNISOLONE; TRIGLYCERIDES; VINCRISTINE;

EID: 0030930283     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C, Peterson RG, Handschumacher RE. L-asparaginase: clinical, biochemical, pharmacological and immunological studies. Ann Intern Med 1971;74: 893-901.
2. Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB, Serpick AA, Selawry OS. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969;281:1028-34.
3. Priest JR, Ramsay NK, Steinherz PG, Tubergan DG, Cairo MS, Sitarz AL, Bishop AJ, White L, Trigg ME, Levitt CJ, Cich JA, Coccia PF. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982;100:984-9.
4. Priest JR, Ramsay NK, Bennet AJ, Krivit W, Edson JR. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr 1982;100: 990-5.
5. Miniero R, Pastore G, Saracco P, Messina M, Lange MM, Fiandino G, Iannacci L, Madon E. Hemostatic changes in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules. Am J Pediatr Hematol Oncol 1986;8:116-20.
6. Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Ito K, Matsuda T. Changes in hematstatic and fibrinolytic proteins in patients receiving L-asparaginase therapy. Am J Hematol 1989;32:20-3.
7. Cremer P, Lakomek M, Beck W, Prindull G. The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukemia. Eur J Pediatr 1988;147:64-7.
8. Konya H, Tamura S, Miyazaki E, Inoue N, Okamoto T, Takemoto Y, Kohsaki M, Kamemaru A, Kakishita E. L-asparaginase-induced hyperlipidemia in a case of acute lymphoblastic leukemia. Jap J Clin Hematol 1991;32:250-4.
9. Chan MK, Varghese Z, Persaud JW, Fernando ON, Moorhead JF. The role of multiple pharmaco-therapy in the pathogenesis of hyperlipidemia after renal transplantation. Clin Nephrol 1981;15:309-13.
10. Morse EE, Viswanathan U. Determination of fibrinogen in plasma. Ann Clin Lab Sci 1978;8:438-41.
11. Tozuka M, Yoshida Y, Tanigami J, Miyachi M, Katsuyama T, Kanai M. Development of an enzyme-linked immunosorbent assay of apolipoprotein E-AII complex in plasma. Clin Chem 1991;37:1645-8.
12. Mahley RW, Hui DY, Innerarity TL, Weisgraber KH. Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-B, E and apo-E receptors. J Clin Invest 1981;68:1197-206.
13. Hui DY, Innerarity TL, Mahley RW. Lipoprotein binding to canine hepatic membranes. Metabolically distinct apo-E and apo-B, E receptors. J Biol Chem 1981;256:5646-55.
14. Havel RJ, Shore VG, Shore B, Bier DM. Role of specific glycopeptides of human serum lipoproteins in the activation of lipoprotein lipase. Circ Res 1970;27:595-600.
15. La Rosa JC, Levy RI, Herbert P, Lux SE, Fredrickson DS. A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun 1970;41:57-62.
16. Wang C-S, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985;75:384-90.
17. Wang C-S, Bass HB, Downs D, Whitmer RK. Modified heparin-Sepharose procedure for determination of plasma lipolytic activities of normolipidemic and hyperlipidemic subjects after injection of heparin. Clin Chem 1981;27:263-8.
18. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apolipoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972;46: 375-82.
19. Innerarity TL, Pitas RE, Mahley RW. Lipoprotein-receptor interactions. Methods Enzymol 1986;129: 542-65.
20. Beisiegel U, Weber W, Havinga JR, Ihrke G, Hui DY, Wernette-Hammond ME, Turck CW, Innerarity TL, Mahley RW. Apolipoprotein E-binding proteins isolated from dog and human liver. Arteriosclerosis 1988; 8:288-97.
21. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989;341:162-4.
22. Zannis VI, Bleslow JL. Characterization of a unique human apolipoprotein E variant associated with typeIII hyperlipoproteinemia. J Biol Chem 1980;255: 1759-62.
23. Zannis VI, Bleslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 1981;20:1033-41.